Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
Tamiya M, Tamiya A, Nakao K, Asami K, Okishio K, Satomu M, Shiroyama T, Morishita N, Suzuki H, Sasada S, Okamoto N, Okishio K, Kawaguchi T, Kobayashi M, Atagi S, Hirashima T, Kawase I. Tamiya M, et al. Among authors: nakao k. Anticancer Res. 2012 Aug;32(8):3553-7. Anticancer Res. 2012. PMID: 22843945
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T. Tamiya M, et al. Among authors: nakao k. Anticancer Res. 2016 Jun;36(6):2939-44. Anticancer Res. 2016. PMID: 27272808
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M, Tamiya A, Suzuki H, Taniguchi Y, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Kumagai T, Atagi S, Imamura F, Hirashima T. Tamiya M, et al. Among authors: nakao k. Invest New Drugs. 2021 Aug;39(4):1106-1112. doi: 10.1007/s10637-021-01076-8. Epub 2021 Feb 5. Invest New Drugs. 2021. PMID: 33544282 Clinical Trial.
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, Takeuchi N, Isa SI, Omachi N, Okamoto N, Suzuki H, Okishio K, Iwazaki A, Imai K, Hirashima T, Atagi S. Tamiya A, et al. Among authors: nakao k. Anticancer Res. 2017 Aug;37(8):4177-4182. doi: 10.21873/anticanres.11806. Anticancer Res. 2017. PMID: 28739703 Clinical Trial.
3,256 results